All stock lists
Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
Healthcare · Biotechnology
7.90-0.13 (-1.62%)
Insider Score
––Not scored
CADL Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
CADL Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| SG&A Expense | 6.95 M | 6.44 M | 4.72 M | 4.75 M | 4.19 M |
| R&D Expense | 19.80 M | 9.84 M | 11.03 M | 8.46 M | 6.99 M |
| Operating Expenses | 26.72 M | 16.26 M | 15.66 M | 13.21 M | 11.18 M |
| Operating Income | -26.72 M | -16.26 M | -15.66 M | -13.21 M | -11.18 M |
| Pretax Income | -38.91 M | -8.86 M | -29.50 M | -11.27 M | -4.80 M |
| Tax Provision | — | — | — | — | — |
| Net Income | -38.91 M | -8.86 M | -29.50 M | -11.27 M | -4.80 M |
| EPS (Basic) | -0.52 | -0.14 | -0.54 | -0.21 | -0.09 |
| EPS (Diluted) | -0.52 | -0.14 | -0.54 | -0.21 | -0.09 |
| Shares Outstanding | 74.13 M | 62.36 M | 54.90 M | 54.89 M | 51.49 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.